Reduced Expression of 11β-Hydroxysteroid Dehydrogenase Type 2 in Preeclamptic Placentas Is Associated With Decreased PPARγ but Increased PPARα Expression

Endocrinology

Volumn 155, Issue 1, 2014, Pages 299-309

  He, Ping ^a   Chen, Zhaoguang ^a   Sun, Qianqian ^a   Li, Yuan ^a   Gu, Hang ^a   Ni, Xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; 2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 CHLORO 5 NITROBENZANILIDE; MITHRAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE; TRANSCRIPTION FACTOR SP1;

ADULT; ARTICLE; BIRTH WEIGHT; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; GENETIC STABILITY; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MODULATION; PREECLAMPSIA; PRIMIPARA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; YOUNG ADULT;

EID: 84891428729     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1350     Document Type: Article

References (42)

1. Roberts JM, Redman CW. Preeclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447-1451.
2. Eiland E, Nzerue C, Faulkner M. 2012 Preeclampsia: J Pregnancy. 2012;2012:586578.
3. Broughton Pipkin F, Rubin PC. Pre-eclampsia-the 'disease of theories'. Br Med Bull. 1994;50:381-396.
4. Causevic M, Mohaupt M. 11beta-hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia. Mol Aspects Med. 2007;28: 220-226.
5. Schoof E, Girstl M, Frobenius W, et al. Decreased gene expression of 11-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab. 2001;86:1313-1317.
6. Alfaidy N, Gupta S, DeMarco C, Caniggia I, Challis Jr. Oxygen regulation of placental 11 beta-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol Metab. 2002;87:4797-4805.
7. Palermo M, Quinkler M, Stewart PM. Apparent mineralocorticoid excess syndrome: an overview. Araq Bras Endocrinol Metabol. 2004;448:687-696.
8. Krozowski Z. The 11-hydroxysteroid dehydrogenases: functions and physiological effects. Mol Cell Endocrinol. 1999;151:121-127.
9. Jansson T, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci. 2007;113:1-13.
10. Marciniak B, Patro-Małysza J, Poniedziałek-Czahkowska E, Kimber-Trojnar Z, Leszczynska-Gorzelak B, Oleszczuk J. Glucocorticoids in pregnancy. Curr Pharm Biotechnol. 2011;12:750-757.
11. Sun K, Ma R, Cui X, et al. Glucocorticoids induce cytosolic phospholipase A2 and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J Clin Endocrinol Metab. 2003;88:5564-5571.
12. Cheng YH, Nicholson RC, King B, Chan EC, Fitter JT, Smith R. Glucocorticoid stimulation of corticotropin-releasing hormone gene expression requires a cyclic adenosine 3,5-monophosphate regulatory element in human primary placental cytotrophoblast cells. J Clin Endocrinol Metab. 2000;85:1937-1945.
13. Guo DF, Uno S, Ishihata A, Nakamura N, Inagami T. Identification of a cis-Acting glucocorticoid responsive element in the rat angiotensin II type 1A promoter. Circ Res. 1995;77:249-257.
14. Seckl Jr. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol. 2001;185: 61-71.
15. Smith SA. Peroxisome proliferator-Activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans. 2002; 30:1086-1090.
16. Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-Activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat. 2012;22:803-841.
17. Wahli W. Peroxisome proliferator-Activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly. 2002;132:83-91.
18. Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly. 2010;140:w13071.
19. Wagner KD, Wagner N. Peroxisome proliferator-Activated receptor +/-(PPAR+/-) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010;125:423-435.
20. Chong HC, Tan MJ, Philippe V, et al. Regulation of epithelial -mesenchymal IL-1 signaling by PPAR +/-is essential for skin homeostasis and wound healing. J Cell Biol. 2009;184:817-831.
21. Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D. PPARs and the placenta. Placenta. 2007;28:65-76.
22. Fournier T, Therond P, Handschuh K, Tsatsaris V, Evain-Brion D. PPAR-And early human placental development. Med Chem. 2008; 15:3011-3024.
23. Ding NZ, Teng CB, Ma H, et al. Peroxisome proliferator-Activated receptor expression and regulation in mouse uterus during embryo implantation and decidualization. Mol Reprod Dev. 2003;66:218-224.
24. McCarthy FP, Drewlo S, English FA, et al. Evidence Implicating Peroxisome Proliferator-Activated Receptor-α in the Pathogenesis of Preeclampsia. Hypertension. 2011;58:882-887.
25. Holdsworth-Carson SJ, Lim R, Mitton A, et al. Peroxisome proliferator-Activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta. 2010;31:222-229.
26. Rodie VA, Young A, Jordan F, Sattar N, Greer IA, Freeman DJ. Human placental peroxisome proliferator-Activated receptor and expression in healthy pregnancy and in preeclampsia and intrauterine growth restriction. J Soc Gynecol Investig. 2005;12:320-329.
27. Julan L, Guan H, van Beek JP, Yang K. Peroxisome proliferatoractivated receptor suppresses 11-hydroxysteroid dehydrogenase type 2 gene expression in human placental trophoblast cells. Endocrinology. 2005;146:1482-1490.
28. Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferator-Activated receptors and their target genes. J Steroid Biochem Mol Biol. 2005;93:99-105.
29. Singh AK, Battu A, Mohareer K, Hasnain SE, Ehtesham NZ. Transcription of human resistin gene involves an interaction of Sp-1 with peroxisome proliferator-Activating receptor (PPAR-). PloS One. 2010;5:e9912.
30. Fu M, Zhang J, Lin Y, et al. Early stimulation and late inhibition of peroxisome proliferator-Activated receptor (PPAR-) gene expression by transforming growth factor in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads. Biochem J. 2003;370:1019-1025.
31. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology. 1986;118: 1567-1582.
32. Gao L, He P, Sha J, et al. Corticotropin-releasing hormone receptor type 1 and type 2 mediate differential effects on 15-hydroxy prostaglandin dehydrogenase expression in cultured Human chorion trophoblasts. Endocrinology. 2007;148:3645-3654.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2+-C T method. Methods. 2001;25:402-408.
34. Zheng L, Zhang D, Chen X, Yang L, Wei YQ, Zha X. Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer. PLoS One. 2012;7:e39119.
35. Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999;69:391-401.
36. WangQ, Fujii H, KnippGT.Expression ofPPARandRXRisoforms in the developing rat and human term placentas. Placenta. 2002; 23:661-671.
37. Holdsworth-Carson SJ, Permezel M, Rice GE, Lappas M. Preterm and infection-driven preterm labor: the role of peroxisome proliferator-Activated receptors and retinoid X receptor. Reproduction. 2009;137:1007-1015.
38. Dy J, Guan H, Sampath-Kumar R, Richardson BS, Yang K. Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery. Placenta. 2008;29:193-200.
39. Holdsworth-Carson SJ, Permezel M, Rice GE, Lappas M. Preterm and infection-driven preterm labor: the role of peroxisome proliferator-Activated receptors and retinoid X receptor. Reproduction. 2009;137(6):1007-1015.
40. Meissner M, Stein M, Urbich C, et al. PPAR-Activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp-1-dependent DNA binding and transactivation. Circ Res. 2004;94:324-332.
41. Li JN, Ge YC, Yang Z, et al. The Sp-1 transcription factor is crucial for the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human placental trophoblasts. J Clin Endocrinol Metab. 2011; 96:E899-E907.
42. McCalla CO, Nacharaju VL, Muneyyirci-Delale O, Glasgow S, Feldman JG. Placental 11-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies. Steroids. 1998;63: 511-515.